Shmeylan A Al Harbi

Shmeylan A Al Harbi


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2018 in Trials
Verified
Journal Article
Open access
PDF file
TGthe MIRACLE trial group
the MIRACLE trial group
YAYaseen M Arabi
Yaseen M Arabi
AAAdel Alothman
Adel Alothman
HBHanan H. Balkhy
Hanan H. Balkhy
AAAbdulaziz Al-Dawood
Abdulaziz Al-Dawood
MHMohamed A. Hussein
Mohamed A. Hussein
It had been more than 5 years since the first case of Middle East Respiratory Syndrome coronavirus infection (MERS-CoV) was recorded, but no specific treatment has been investigated in randomized clinical trials. Results from in vitro and animal studies suggest that a combination of lopinavir/ritonavir and interferon-β1b (IFN-β1b) may be effective against MERS-CoV. The aim of this study is to investigate the efficacy of treatment with a combination of lopinavir/ritonavir and recombinant IFN-β1b provided with standard supportive care, compared to treatment with placebo provided with standard supportive care in patients with laboratory-confirmed MERS requiring hospital admission. The protocol is prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. Hospitalized adult patients with laboratory-confirmed MERS will be enrolled in this recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind randomized controlled trial. The trial is initially designed to include 2 two-stage components. The first two-stage component is designed to adjust sample size and determine futility stopping, but not efficacy stopping. The second two-stage component is designed to determine efficacy stopping and possibly readjustment of sample size. The primary outcome is 90-day mortality. This will be the first randomized controlled trial of a potential treatment for MERS. The study is sponsored by King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. Enrollment for this study began in November 2016, and has enrolled thirteen patients as of Jan 24-2018. ClinicalTrials.gov, ID: NCT02845843. Registered on 27 July 2016.

3 January 2020 in Trials
Verified
Journal Article
Open access
PDF file
TGthe Saudi Critical Care Trials group
the Saudi Critical Care Trials group
YAYaseen M Arabi
Yaseen M Arabi
AAAyed Y. Asiri
Ayed Y. Asiri
Abdullah M. AsiriAbdullah M. Asiri
Abdullah M. Asiri
HJHani A. Aziz Jokhdar
Hani A. Aziz Jokhdar
MHMohamed A. Hussein
Mohamed A. Hussein
The MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-β1b) investigates the efficacy of a combination therapy of lopinavir/ritonavir and recombinant interferon-β1b provided with standard supportive care, compared to placebo provided with standard supportive care, in hospitalized patients with laboratory-confirmed MERS. The MIRACLE trial is designed as a recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind randomized controlled trial. The aim of this article is to describe the statistical analysis plan for the MIRACLE trial. The primary outcome is 90-day mortality. The primary analysis will follow the intention-to-treat principle. The MIRACLE trial is the first randomized controlled trial for MERS treatment.Trial registration: ClinicalTrials.gov,NCT02845843. Registered on 27 July 2016.

5 February 2016 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
SHShmeylan A Al Harbi
Shmeylan A Al Harbi
HTHani Tamim
Hani Tamim
HAHasan M Al-Dorzi
Hasan M Al-Dorzi
MSMusharaf Sadat
Musharaf Sadat
YAYaseen M Arabi
Yaseen M Arabi
Antiplatelet therapy may attenuate the undesirable effects of platelets on the inflammatory cascades in critical illness. The objective of this study was to evaluate the association between aspirin therapy during intensive care unit (ICU) stay and all-cause mortality. This was a nested cohort study within two randomized controlled trials in which all enrolled patients (N = 763) were grouped according to aspirin intake during ICU stay. The primary endpoints were all-cause ICU mortality and hospital mortality. Secondary endpoints included the development of severe sepsis during the ICU stay, ICU and hospital length of stay and the duration of mechanical ventilation. Propensity score was used to adjust for clinically and statistically relevant variables. Of the 763 patients, 154 patients (20 %) received aspirin. Aspirin therapy was not associated with a reduction in ICU mortality (adjusted OR 1.18, 95 % CI 0.69–2.02, P = 0.55) nor with hospital mortality (adjusted OR 0.95, 95 % CI 0.61–1.50, P = 0.82). Aspirin use had no preferential association with mortality among any of the study subgroups. Additionally, aspirin therapy was associated with higher risk of ICU-acquired severe sepsis, and increased mechanical ventilation duration and ICU length of stay. Our study showed that the use of aspirin in critically ill patients was not associated with lower mortality, but rather with an increased morbidity. ISRCTN07413772 and ISRCTN96294863 .

6 August 2011 in BMC Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SHShmeylan A Al Harbi
Shmeylan A Al Harbi
HTHani Tamim
Hani Tamim
YAYaseen M Arabi
Yaseen M Arabi
The effect of statin therapy on mortality in critically ill patients is controversial, with some studies suggesting a benefit and others suggesting no benefit or even potential harm. The objective of this study was to evaluate the association between statin therapy during intensive care unit (ICU) admission and all-cause mortality in critically ill patients.

1 July 2023 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
OAOhoud Aljuhani
Ohoud Aljuhani
GKGhazwa B. Korayem
Ghazwa B. Korayem
AAAli Faris Altebainawi
Ali Faris Altebainawi
MAMeshal S. Alotaibi
Meshal S. Alotaibi
NANoura A. Alrakban
Noura A. Alrakban
KSKhalid Al Sulaiman
Khalid Al Sulaiman
Oseltamivir has been used as adjunctive therapy in the management of patients with COVID-19. However, the evidence about using oseltamivir in critically ill patients with severe COVID-19 remains scarce. This study aims to evaluate the effectiveness and safety of oseltamivir in critically ill patients with COVID-19. This multicenter, retrospective cohort study includes critically ill adult patients with COVID-19 admitted to the intensive care unit (ICU). Patients were categorized into two groups based on oseltamivir use within 48 hours of ICU admission (Oseltamivir vs. Control). The primary endpoint was viral load clearance. A total of 226 patients were matched into two groups based on their propensity score. The time to COVID-19 viral load clearance was shorter in patients who received oseltamivir (11 vs. 16 days, p = 0.042; beta coefficient: −0.84, 95%CI: (−1.33, 0.34), p = 0.0009). Mechanical ventilation (MV) duration was also shorter in patients who received oseltamivir (6.5 vs. 8.5 days, p = 0.02; beta coefficient: −0.27, 95% CI: [−0.55,0.02], P = 0.06). In addition, patients who received oseltamivir had lower odds of hospital/ventilator-acquired pneumonia (OR:0.49, 95% CI:(0.283,0.861), p = 0.01). On the other hand, there were no significant differences between the groups in the 30-day and in-hospital mortality. Oseltamivir was associated with faster viral clearance and shorter MV duration without safety concerns in critically ill COVID-19 patients.

1 October 2017 in Saudi Journal of Anaesthesia
Verified
Journal Article
Open access
PDF file
AAAlaa Al-Anazi
Alaa Al-Anazi
LALowloa Al-Swaidan
Lowloa Al-Swaidan
MAMaha Al-Ammari
Maha Al-Ammari
TATariq Al-Debasi
Tariq Al-Debasi
AAAbdulmalik M. Alkatheri
Abdulmalik M. Alkatheri
AAAbdulkareem M. Al-Bekairy
Abdulkareem M. Al-Bekairy
Background: Vaso-occlusive crisis (VOC) is one of the acute complications of sickle-cell disease (SCD). Treatment mainly relies on hydration and pain control by analgesics. The specific aim of this study was to assess potential health outcomes within the first 72 h of admission between intermittent and patient-controlled analgesia (PCA) by opioids among VOC patients. Methods: A retrospective chart review study was conducted to determine SCD patients with VOC. Using the hospital electronic system, the following data were collected: patient's age, gender, blood pressure, heart rate, respiratory rate, oxygen saturation, and pain score on admission and daily for 3 days as well as the cumulative opioid analgesic dose for 72 h which is reported as morphine equivalent. Results: One hundred and seventeen patients were screened over a period of 5 years. Of those, 99 (84.6%) met the study inclusion criteria, and 18 patients (15.4%) were excluded from the study. During the first 72 h of admission, a significant reduction in pain score was observed in patients on intermittent intravenous (IV) administration compared to those in the PCA group (P < 0.0004) where the mean pain scores were 3 and 5, respectively. The total amount of morphine administered over 72 h of admission was significantly higher in PCA group (777 ± 175 mg) as compared to the intermittent IV administration group (149 ± 74 mg) (P < 0.000003). Clinically significant hypotension or respiratory depression was not observed in both groups over the 72 h of admission. Conclusion: During the first 72 h of admission, intermittent IV administration of morphine was more effective than PCA infusion in pain control.